Abdelrahman M. Elsayed

Madinat An Nasr, C 11651, Egypt

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Clinical phenotypes of uveal melanoma in patients with germline pathogenic/likely pathogenic BAP1 variants.

Clinical phenotypes of uveal melanoma in patients with germline pathogenic/likely pathogenic BAP1 variants.

Journal: medRxiv : the preprint server for health sciences
Published: July 10, 2026

BAP1 Loss Induces Senescence and Enhances the Response to Radiation Therapy and Senolytics.

BAP1 Loss Induces Senescence and Enhances the Response to Radiation Therapy and Senolytics.

Journal: bioRxiv : the preprint server for biology
Published: February 23, 2026

Corrigendum to "An overview of BAP1 biological functions and current therapeutics" [BBA - Reviews on Cancer 1880 (2025) 189267].

Corrigendum to "An overview of BAP1 biological functions and current therapeutics" [BBA - Reviews on Cancer 1880 (2025) 189267].

Journal: Biochimica et biophysica acta. Reviews on cancer
Published: March 23, 2025

Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD).

Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD).

Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: November 24, 2024

An overview of BAP1 biological functions and current therapeutics.

An overview of BAP1 biological functions and current therapeutics.

Journal: Biochimica et biophysica acta. Reviews on cancer
Published: September 29, 2024

Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer.

Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer.

Journal: Pharmacological reports : PR
Published: August 11, 2021

PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.

PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.

Journal: International journal of molecular sciences
Published: December 22, 2020

Back to the Future: Rethinking the Great Potential of lncRNAS for Optimizing Chemotherapeutic Response in Ovarian Cancer.

Back to the Future: Rethinking the Great Potential of lncRNAS for Optimizing Chemotherapeutic Response in Ovarian Cancer.

Journal: Cancers
Published: June 24, 2020

Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer.

Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer.

Journal: International journal of molecular sciences
Published: March 14, 2020

All-trans retinoic acid potentiates cisplatin-induced kidney injury in rats: impact of retinoic acid signaling pathway.

All-trans retinoic acid potentiates cisplatin-induced kidney injury in rats: impact of retinoic acid signaling pathway.

Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: September 06, 2015
Showing 1-10 of 10

Last Updated: 09/26/2026